Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mexican consensus on the approach to and treatment of acute variceal bleeding.

Revista de gastroenterologia de Mexico (English)·2025
Same author

Incidence and causes of retreatments after monovision induced by LASIK in myopic patients without a previous trial of contact lens induced monovision.

Archivos de la Sociedad Espanola de Oftalmologia·2024
Same author

Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2024
Same author

Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice.

Alimentary pharmacology & therapeutics·2024
Same author

Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain.

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2024
Same journal

Acute Rejection Mediated by Preformed Anti-HLA-C Antibody in a Kidney Transplant Patient: A Case Report.

Transplantation proceedings·2026
Same journal

Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.

Transplantation proceedings·2026
Same journal

Analysis of the Cost of Maintaining Effective Donors and Nondonors of Organs and Tissues in Intensive Care Units.

Transplantation proceedings·2026
Same journal

Adolescence and Pediatric Heart Transplantation: Impact of Non-Adherence on Mortality: A Single-Center Experience.

Transplantation proceedings·2026
Same journal

Impact of Family-Based Care on the Outcome of Brain Death and Humanization in the Process of Multiple Organ Donation: Case Report.

Transplantation proceedings·2026
Same journal

Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation.

Transplantation proceedings·2026
See all related articles

Related Experiment Video

Updated: May 16, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Initial immunosuppression with or without basiliximab: a comparative study.

R M Martín-Mateos1, J Graus, A Albillos

  • 1Hospital Ramón y Cajal, Madrid, Spain. r.martinmateos@me.com

Transplantation Proceedings
|November 14, 2012
PubMed
Summary
This summary is machine-generated.

Basiliximab use in liver transplant patients significantly reduced renal failure and rejection episodes. This immunosuppressive strategy, with delayed calcineurin inhibitors, offers a promising approach to improve post-transplant kidney outcomes.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Experiment Videos

Last Updated: May 16, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation Medicine

Background:

  • Acute kidney injury (AKI) and chronic kidney disease are common complications after liver transplantation, affecting a significant percentage of patients.
  • Basiliximab, a monoclonal antibody, is used to prevent organ rejection, especially in patients with kidney dysfunction, by allowing delayed calcineurin inhibitor use.

Purpose of the Study:

  • To evaluate the immunosuppressive efficacy of basiliximab.
  • To assess basiliximab's impact on renal failure incidence, hospital and ICU lengths of stay, and infection rates in liver transplant recipients.

Main Methods:

  • A controlled, nonrandomized study compared two immunosuppressive regimens in liver transplant patients from January 2010 to December 2011.
  • Group I received tacrolimus and corticosteroids with mycophenolate mofetil for renal failure.
  • Group II received corticosteroids and mycophenolate mofetil with basiliximab (days 0 and 4) and delayed tacrolimus (day 3).

Main Results:

  • Basiliximab (Group II) showed a significantly lower incidence of renal failure requiring replacement therapy (3.03% vs. 25%, P = .014).
  • Acute cellular rejection episodes treated with corticosteroids were also significantly lower in Group II (3.03% vs. 25%, P = .014).
  • Infection rates and hospital/ICU stays were lower in the basiliximab group, though not statistically significant.

Conclusions:

  • Administering basiliximab with delayed calcineurin inhibitors is an effective strategy.
  • This approach may reduce the incidence of acute kidney injury requiring renal replacement therapy post-liver transplantation.